Knowledge of the clinical outcomes associated with continuous glucose monitor (CGM) use is crucial when creating Medicaid policy that ensures that people with diabetes receive evidence-based care that improves their health and well-being. The resources in this section can help states understand and effectively convey the importance of expanding access to CGMs to improving health outcomes.
Partnering for Better Health: Using Continuous Glucose Monitoring and Clinical Pharmacist Collaboration to Improve Glycemic Control in Underserved Patients with Type 2 Diabetes
Assesses changes in HbA1c levels among non-insulin and insulin-requiring type 2 diabetes primary care patients prescribed a CGM , finding statistically significant reductions in mean HbA1c levels. Patients who visited a clinical pharmacist during their clinic visit exhibited greater reductions in HbA1c levels.
Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking
Reviews the evidence base of the benefits of CGM usage among individuals with type 2 diabetes treated with basal insulin only and/or noninsulin therapies and finds CGM use is associated with improvements in HbA1c and/or other key outcome measures.
Beyond A1C: Exploring Continuous Glucose Monitoring Metrics in Managing Diabetes
Describes the benefits and limitations of CGM use for diabetes treatment, CGM usage in clinical settings, and the application of CGM to advanced diabetes technology.
Comparing Clinical Outcomes Between Two Continuous Glucose Monitors: Similar Diabetes-Related Events, All-Cause Hospitalizations and HbA1c Reductions in Type 1 and Type 2 Diabetes
Studies the clinical outcomes of two CGMs (Dexcom and FreeStyle Libre) in people with type 1 and type 2 diabetes and finds similar rates of acute diabetes events, hospitalizations, and HbA1c reductions between these devices.
Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
Evaluates the benefit of CGM use and finds that seven years later, A1c was significantly lower for those who gained access to a CGM within the first year of type 1 diabetes diagnosis versus those with later CGM use or none at all.
Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
Finds that CGM use over eight months among adults with insulin-treated type 2 diabetes resulted in significantly decreased HbA1C.
Flash Continuous Glucose Monitoring: A Summary Review of Recent Real-World Evidence
Analyzes recent flash CGM literature to draw conclusions on the clinical and fiscal impact of flash CGM utilization.
Continuous Glucose Monitoring for Underserved and Minority Patients with Type 2 Diabetes in an Interprofessional Internal Medicine Clinic
Finds that CGM use is associated with reductions in average blood glucose levels and other promising clinical outcomes among a small sample of mostly patients of color served by a safety-net health care facility. CGM service and follow-up care was delivered by an interdisciplinary care team, including a physician, pharmacist, and dietician.
Utilization of Continuous Glucose Monitors Is Associated with Reduction in Inpatient and Outpatient Emergency Acute Diabetes Events Regardless of Prior Blood Test Strip Usage
Analyzes whether CGM efficacy depends on blood test strip usage prior to CGM initiation and found that CGM use was associated with reduced acute diabetes events regardless of baseline blood finger stick use.
Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials
Reviews literature on differences between CGM and standard care methods for glycemic control for both type 1 and type 2 diabetes and highlights the efficacy of CGM compared to other treatment methods.